$Plus Therapeutics (PSTV.US)$ NEWS Plus Therapeutics to Host...
NEWS
Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial
Plus Therapeutics, Inc. (Nasdaq: PSTV) will host an investor call on May 9th, 2024, to discuss the acquisition of CNSide assets and provide updates on the FORESEE clinical trial. The company aims to leverage the acquired assets for CNS cancers and share key insights with investors.
Positive
Strategic acquisition of CNSide assets to enhance CNS cancer diagnostic capabilities
Rationale for the acquisition will be discussed by President and CEO Dr. Marc H. Hedrick
Updates on topline data from the FORESEE trial and business plan to leverage acquired assets
Positive
Strategic acquisition of CNSide assets to enhance CNS cancer diagnostic capabilities
Rationale for the acquisition will be discussed by President and CEO Dr. Marc H. Hedrick
Updates on topline data from the FORESEE trial and business plan to leverage acquired assets
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
721Followers
75Following
4610Visitors
Follow